Transdermal Drug Delivery Patches 2026 — PatSnap Eureka
Transdermal Drug Delivery Patch Technology Landscape 2026
From foundational passive matrix architectures to microneedle arrays, electrotransport systems, and smart adherence patches — explore four decades of patent and literature signals shaping the future of transdermal drug delivery.
Five Architectural Classes of Transdermal Drug Delivery
Transdermal drug delivery systems range from foundational passive diffusion architectures to active electrotransport and next-generation microneedle platforms — each addressing the stratum corneum barrier through distinct mechanisms.
Passive Matrix & Reservoir Systems
The foundational approach involves dispersing or dissolving a drug in a polymer matrix or enclosing a liquid drug formulation in a membrane-controlled reservoir. Drug flux is governed by concentration gradients and polymer diffusion coefficients. This cluster remains commercially dominant and serves as the baseline against which newer technologies are compared. Schwarz GmbH established the rubber-based controlled-release matrix as early as 1986, covering beta blockers, steroid hormones, and cardiac drugs.
Commercially dominant baselineIontophoresis, Electroporation & Sonophoresis
Active enhancement overcomes the stratum corneum barrier via applied electrical current (iontophoresis) or pulsed electric fields (electroporation) to drive ionic or polar drug molecules through the skin. These systems enable delivery of higher-molecular-weight compounds and allow programmable dosing profiles. Teva Pharmaceuticals' iontophoretic migraine patches use two-stage current delivery: 3 mA for 45 minutes, then 1.5 mA sustained for sumatriptan delivery, demonstrating superiority over oral and nasal dosing.
Programmable dosing profilesMicroneedle Array Patches
Microneedle patches physically breach the stratum corneum with needles of 200–900 µm height to create transient microchannels for drug permeation. Sub-types include solid coated MNs, dissolving MNs (biodegradable polymer tips that dissolve in skin), semi-dissolving MNs, and rapidly separable MNs for long-acting therapies. Leo Pharma's biodegradable-tip MN patches enable sustained release over ≥2 days for psoriasis, while Shilla Industrial's star-shaped pyramid geometry expands surface area relative to conventional conical designs. Learn more about life sciences patent analytics.
Most active filings from 2017 onwardNanocarrier-Integrated & Novel Excipient Systems
Integration of nanoparticulate carriers — polymeric nanoparticles, liposomes, solid lipid nanoparticles — into the patch matrix enables delivery of macromolecular drugs, improves drug stability, and provides controlled release kinetics. Deep eutectic systems (DES) emerge as a newer excipient class capable of solubilizing proteins, insulin, and nanoparticles for transdermal permeation. The FDA-approved PLGA polymer platform is highlighted as particularly relevant for sustained transdermal release, as reviewed by the advanced materials research community.
DES enables protein & insulin deliveryAssignee Landscape & Application Domain Distribution
Patent record counts and application domain signals derived from the PatSnap Eureka dataset spanning 1986–2026.
Top Assignees by Patent Record Count
Phosphagenics (5 records) and Leo Pharma, Hisamitsu, and Teva (4 records each) lead this dataset; ALZA, Durect, Nitto Denko, Veradermics, Emergex, and LTS Lohmann each hold 2 records.
Application Domain Distribution
Neurology & pain management is the largest identifiable application cluster; hormonal therapy, cardiovascular, immunology, and emerging CNS/psychedelic indications round out the landscape.
From Fentanyl Patches to Psilocybin Microprotrusions
The largest identifiable application cluster in this dataset is neurology and pain management. Fentanyl, sumatriptan (migraine), topiramate (epilepsy/migraine), almotriptan, and methylphenidate (ADHD) all appear as target drugs. Life sciences patent analytics confirms that ADHD methylphenidate transdermal systems are FDA-approved in the US, with more than 20 medications in aggregate approved for transdermal delivery according to academic literature in this dataset.
Hormonal and contraceptive therapy is anchored by Bayer's low-dose transdermal patches with high drug release (HU, 2017) targeting contraceptive progestin/estrogen combinations — gestodene and ethinylestradiol — with 7-day patch cycling. Rapidly separable microneedle patches for long-acting contraceptives are identified as an emerging direction in the 2022 Wuhan University review literature.
Cardiovascular and metabolic disease targets include hypertension drugs (losartan potassium), statins (simvastatin, rosuvastatin), beta blockers, calcium antagonists, and cardiac drugs. The Schwarz GmbH foundational patent (AU, 1986) explicitly claims beta blockers and calcium antagonists. Pulmonary arterial hypertension is a noted newer application vertical per the 2021 People's University literature review.
The most novel indication cluster in this dataset is psychedelic-assisted therapy. Emergex USA Corporation's filing (IL, 2022) covers intracutaneous delivery of psilocybin, LSD, or MDMA for depression, anxiety, PTSD, migraine, and cluster headache at doses of 0.2–10 mg per patch via microprotrusions. The FDA and EMA are actively engaged with psychedelic-assisted therapy regulatory pathways, making precise transdermal dosimetry an increasingly relevant capability.
For antimicrobial applications, bacterial cellulose/polycaprolactone composite patches loaded with amoxicillin, ampicillin, and kanamycin fabricated via electrohydrodynamic (EHD)-3D printing demonstrate activity against both Gram-positive and Gram-negative strains (University Politehnica of Bucharest, 2021).
Five Directional Signals Shaping the Next Generation of Transdermal Patches
Based on the most recent filings and publications in this dataset, these clusters represent the leading edge of innovation in transdermal drug delivery technology.
Stimuli-Responsive & Closed-Loop Patch Systems
City University of Hong Kong's touch-actuated microneedle array patch (TMAP) enables "press and release" closed-loop delivery of insulin-loaded liquid drugs (2018). A 2021 Bangladesh study of thermoresponsive paraffin film patches controlled by a portable mini-heater achieved 80% drug release within 6 hours — an accessible implementation of on-demand release.
Integrated Patch Monitoring & Smart Adherence
The Transdermal Patch with integrated timer indicator filed by Singh, Arwinder (EP, 2026, active) signals a convergence of drug delivery and digital health. The 2021 University of Warwick terahertz (THz) sensing study for non-invasive in vivo monitoring of skin hydration under patches represents a sensing technology that could be incorporated into future smart patch architectures.
Top Patent Assignees by Record Volume & Jurisdiction
Israel (IL) accounts for the largest share of filings in this dataset — reflecting its role as a bilateral patent filing destination under cooperation agreements. The WIPO PCT system and EPO underpin the international filing strategies visible across this landscape.
| Assignee | Records in Dataset | Primary Jurisdictions | Technology Focus |
|---|---|---|---|
| Phosphagenics Limited | 5 | ILEP | Tocopherol phosphate matrix, enhanced permeation |
| Leo Pharma A/S | 4 | ILEPSG | Biodegradable MN tips, psoriasis, sustained ≥2 day release |
| Hisamitsu Pharmaceutical Co., Inc. | 4 | US | Medical transdermal patch, commercial product line |
| Teva Pharmaceuticals International GmbH | 4 | IL | Iontophoretic migraine patches (sumatriptan), active delivery |
| LTS Lohmann Therapie-Systeme AG | 2 | IL | Skin-tone-matched cosmetically discreet patches |
| Nitto Denko Corporation | 2 | EPHK | Actuator-based electroporation delivery system |
| Veradermics Incorporated | 2 | IL | Immunostimulatory dual-length MN, Candida antigen delivery |
| Emergex USA Corporation | 2 | IL | Psilocybin/LSD/MDMA coated microprotrusions (0.2–10 mg) |
| ALZA Corporation | 2 | USIL | Foundational iontophoresis, fentanyl patch |
| Durect Corporation | 2 | AU | Implantable drug delivery patch |
Track assignee activity across all jurisdictions
Monitor Phosphagenics, Leo Pharma, Teva, and 10,000+ other assignees with real-time patent alerts in PatSnap Analytics.
Where the White Space Is in Transdermal Patch IP
Microneedle platforms are the primary white-space opportunity. Within this dataset, dissolving, coated, and rapidly separable MN architectures are receiving the most active IP development across multiple assignees and jurisdictions. R&D teams not yet active in MN should assess whether their target drug molecules — particularly macromolecules, proteins, vaccines, and CNS compounds — can benefit from this bypass of the stratum corneum barrier. The NIH has published extensively on microneedle-mediated vaccine delivery as a priority area for needle-free immunization.
Active enhancement remains under-exploited outside migraine. Teva's iontophoretic migraine patches and Nitto Denko's electroporation system are the primary active-delivery patent holders in this dataset. For ionic or polar drug candidates currently limited to injection, iontophoretic patch platforms represent an accessible bridge to non-invasive delivery with substantial differentiation potential. PatSnap Analytics can identify white space in the iontophoresis filing landscape.
Israel is a disproportionately active filing jurisdiction. IP strategists filing in pharmaceutical delivery should include IL in their PCT national phase strategies, as Phosphagenics, Leo Pharma, Teva, Veradermics, Emergex, and LTS Lohmann all hold active or pending IL grants in this dataset.
Deep eutectic systems and nanocarrier integration are formulation-level differentiators. For assignees holding passive patch platforms, loading with PLGA nanoparticles, polymeric nanoparticles, or DES formulations is a near-term formulation innovation pathway that does not require device-level redesign but meaningfully extends the range of deliverable drug classes — particularly macromolecules and hydrophilics. Review the advanced materials and chemicals solution for formulation IP analysis.
Patient adherence and digital health integration will become regulatory differentiators. The 2026 EP patent for a patch-integrated timer indicator and the broader literature on medication nonadherence signal that payers and regulators are increasingly attentive to real-world adherence outcomes. Products that embed compliance monitoring into patch design will carry differentiated value propositions in chronic disease markets. Explore how PatSnap customers are using innovation intelligence to drive R&D strategy.
Transdermal Drug Delivery Patches — key questions answered
The five distinct architectural classes are: (1) Passive matrix and reservoir patches — the foundational architecture, relying on drug diffusion through a polymer matrix or across a rate-controlling membrane; (2) Electrotransport and active enhancement patches — iontophoresis, electroporation, and ultrasound-mediated delivery; (3) Microneedle array patches — physical penetration of the stratum corneum using microscale projections, either solid, dissolving, or coated; (4) Nanocarrier-loaded patches — integration of liposomes, polymeric nanoparticles, or solid lipid nanoparticles into matrix or reservoir systems; (5) Stimuli-responsive and smart patches — on-demand drug release triggered by temperature, pH, or external energy; and patches with integrated timing/monitoring functions.
Phosphagenics Limited leads with 5 records across IL and EP jurisdictions, followed by Leo Pharma A/S (4 records: IL, EP, SG), Hisamitsu Pharmaceutical Co., Inc. (4 records: US), and Teva Pharmaceuticals International GmbH (4 records: IL). Other notable assignees include LTS Lohmann Therapie-Systeme AG, Nitto Denko Corporation, Veradermics Incorporated, Emergex USA Corporation, ALZA Corporation, and Durect Corporation, each with 2 records.
The stratum corneum remains the primary rate-limiting barrier across all passive approaches. Chemical permeation enhancers (e.g., DMSO, isopropyl myristate, eugenol, d-limonene), physical enhancement (microneedles, iontophoresis), and formulation strategies (microemulsions, deep eutectic systems, nanoparticles) are the primary levers used to overcome this barrier, as evidenced across the retrieved literature.
Based on the most recent filings and publications (2021–2026), four primary directional signals are identifiable: (1) Stimuli-responsive and closed-loop patch systems enabling on-demand drug release; (2) Integrated patch monitoring and smart adherence, including the 2026 EP patent for a patch-integrated timer indicator; (3) Advanced microneedle manufacturing and geometries, such as Shilla Industrial's star-shaped pyramid microneedle geometry (EP, 2023); (4) Psychedelic and CNS indication expansion, represented by Emergex USA Corporation's psilocybin/LSD/MDMA microprotrusion patches (IL, 2022); and (5) Skin-on-a-chip testing platforms to reduce animal testing dependency.
Israel (IL) accounts for the largest share of filings in this dataset. This reflects Israel's role as a bilateral patent filing destination under cooperation agreements rather than necessarily domestic innovation origin. Assignees including Phosphagenics, Leo Pharma, Teva, Veradermics, Emergex, LTS Lohmann, and ALZA all hold active or pending IL grants in this dataset, with approximately 15+ IL records identified.
Microneedle (MN) patches physically breach the stratum corneum with needles of 200–900 µm height to create transient microchannels for drug permeation, bypassing the diffusion limitations of passive matrix systems. Sub-types include solid coated MNs, dissolving MNs (biodegradable polymer tips that dissolve in skin), semi-dissolving MNs, and rapidly separable MNs for long-acting therapies. This cluster represents the most active area of new patent filing in the dataset from 2017 onward, whereas passive matrix and reservoir patches remain commercially dominant as the baseline architecture.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka AI Your Patent QuestionsAccelerate Your Transdermal Patch R&D with AI Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map technology landscapes, identify white space, and track assignee activity across 2B+ data points.
References
- Transdermal Drug Patch Containing Water-Swellable Polymer — Schwarz GmbH, 1986, AU
- Multicompartmentalized Dermal and Transdermal Patches — Novartis AG (formerly Ciba-Geigy AG), 1987, AU
- Multicompartmentalized Transdermal Patch for Administering Drugs to the Skin — Ciba-Geigy Corporation, 1988, US
- Electrotransport Drug Delivery Patch — ALZA Corporation, 1994, US
- Pharmaceutical, Cosmetic or Dermo-Pharmaceutical Patch — L'Oreal, 1998, CA
- Release Controlled Transdermal Therapeutic System — Lead Chemical Co., Ltd., 1999, AU
- Medical Transdermal Patch — Hisamitsu Pharmaceutical Co., Inc., 2003, US
- Medical Active Substance Patch with Reduced Optical Conspicuousness — LTS Lohmann Therapie-Systeme AG, 2006, IL
- Implantable Drug Delivery Patch — Durect Corporation, 2007, AU
- Transdermal Patches for the Delivery of Anti-Migraine Compounds — Teva Pharmaceuticals International GmbH, 2009, IL
- Transdermal Delivery Patch — Phosphagenics Limited, 2012, IL
- Transdermal Patch for Administering Fentanyl — ALZA Corporation, 2016, IL
- Low-Dose Transdermal Patches with High Drug Release — Bayer Intellectual Property GmbH, 2017, HU
- Microneedle Patch for Delivering an Active Ingredient to Skin — Leo Pharma A/S, 2017, IL
- Transdermal Drug Delivery Patch System — Nitto Denko Corporation, 2018, EP
- Transdermal Delivery Patch — Phosphagenics Limited, 2020, EP
- Microneedle Patch for Delivering an Active Ingredient to the Skin — Leo Pharma A/S, 2021, EP
- Microneedle Patch for Immunostimulatory Drug Delivery — Veradermics Incorporated, 2022, IL
- Transdermal Drug Delivery Devices Having Psilocybin, LSD or MDMA Coated Microprotrusions — Emergex USA Corporation, 2022, IL
- Method for Manufacturing a Transdermal Drug Delivery Patch — Shilla Industrial Co., Ltd., 2023, EP
- Transdermal Drug Delivery System for Delivering a Drug to a Patient — Li, Weiyong, 2025, EP
- Transdermal Patch (integrated timer indicator) — Singh, Arwinder, 2026, EP
- Transdermal Drug Delivery Patch — Passport Technologies, Inc., 2026, AU
- World Intellectual Property Organization (WIPO) — PCT Patent Filing System
- European Patent Office (EPO) — Transdermal Drug Delivery Patent Database
- U.S. Food and Drug Administration (FDA) — Approved Transdermal Drug Products
- European Medicines Agency (EMA) — Transdermal Patch Regulatory Guidance
- National Institutes of Health (NIH) — Microneedle Vaccine Delivery Research
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This landscape is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.